<DOC>
	<DOCNO>NCT00463515</DOCNO>
	<brief_summary>The aim study evaluate whether combine carboplatin-gemcitabine base induction chemotherapy weekly cisplatin standard thoracic radiotherapy possible obtain optimal efficacy minimal toxicity . Patients treat 3 cycle induction chemotherapy , unless occurrence early intrathoracic progression disease . The induction chemotherapy follow chemo-radiotherapy .</brief_summary>
	<brief_title>Evaluation Carboplatin Plus Gemcitabine Followed Concomitant Chemoradiation Non-resectable Stage III NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>cytological histologically proven NSCLC unresectable stage III NSCLC presence least one measurable lesion ( RECIST criterion ) adequate haematological , renal hepatic function adequate lung function reserve good condition , weight loss &lt; 10 % previous 6 month , life expectancy &gt; 3 month previous chemotherapy NSCLC distant metastasis pleural pericardial effusion treatment malignant disease past serious concomitant medical psychiatric disease active uncontrolled infection time inclusion interstitial lung disease autoimmune systemic disease potential involvement lung concomitant use amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>lung cancer</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>chemo-radiotherapy</keyword>
</DOC>